New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma

Exclusion Criteria

• •Life-threatening asthma within past year or during Run-in Period.
• •History of systemic corticosteroid medication within 3 months before Screening Visit.
• •History of omalizumab use within the past 6 months.
• •History of leukotriene receptor antagonist use, e.g., montelukast, within the past week.
• •Current evidence of history of any clinically significant disease or abnormality including uncontrolled hypertension, uncontrolled coronary artery disease, congestive heart failure, myocardial infarction, or cardiac dysrhythmia.
• •Upper or lower respiratory infection within 4 weeks prior to Screening Visit or during Run-in Period.
• •Significant, non-reversible, pulmonary disease (e.g., chronic obstructive pulmonary disease \[COPD\], cystic fibrosis, bronchiectasis).
• •Known Human Immunodeficiency Virus (HIV)-positive status.
• •Smoking history equivalent to "10 pack years".
• •Current smoking history within 12 months prior to Screening Visit.